MARC Record from harvard_bibliographic_metadata

LEADER: 04045pam a22003494a 4500
001 010521721-2
005 20070606085615.0
008 070604s2007 maua b 001 0 eng
010 $a 2006021436
020 $a9780763747459
020 $a0763747459
035 0 $aocm70256548
040 $aDNLM$cDNLM
041 0 $aeng
042 $apcc
050 00 $aRC280.P7$bR67 2007
060 00 $a2007 A-998
060 10 $aWJ 762$bR796m 2007
245 10 $aMolecular oncology of prostate cancer /$cedited by Jeffrey S. Ross and Christopher S. Foster.
260 $aSudbury, Mass. :$bJones and Bartlett Publishers,$cc2007.
300 $aix, 534 p., 16 p. of plates :$bill. (some col.) ;$c29 cm.
504 $aIncludes bibliographical references and index.
505 0 $aProstate cancer and molecular medicine -- Molecular diagnostic techniques in prostate cancer -- Molecular epidemiology of prostate cancer -- Prostate cancer stem cells -- Prostate cancer screening and chemoprevention -- Molecular methods, including reverse transcriptase polymerase chain reaction and proteomics, for prostate cancer screening and detection of recurrance and micrometastasis -- Genomic classification of prostate carcinoma -- Pathology of premalignant lesions and adenocarcinoma of prostate -- Overview of prognostic and predictive factors in prostate cancer -- Cytogenetics and molecular genetics of prostate cancer -- DNA ploidy of S phase analysis in prostate cancer -- Cell proliferation markers and cell cycle regulators in prostate cancer -- Targeted therapies for cancer; integrating diagnostics and therapeutics -- The androgen receptor and hormone-based therapies -- HER-2 and anti-HER-2 targeted therapies --
505 0 $aEpidermal growth factor receptor and other growth factors and receptors -- Proteases: targets of tumor invasion and metastasis -- Angiogenesis and angiogenesis inhibitors: applications in adenocarcinoma of the prostate -- Cell adhesion molecules in prostate cancer -- Cell survival, apoptosis, and proapoptotic therapies -- Oncogenes -- p53 and tumor suppressor genes in prostate cancer -- Ubiquitin pathway and proteasome inhibitors -- Significance of DNA methylation in prostate cancer initiation and progression -- Bioinformatics, computational biology, and morphometrics -- Prostate-specific membrane antigen and other cell surface protein targets for antibody-based therapeutics and immunotherapy in prostate cancer -- Gene therapy and immunotherapy for prostate cancer -- Pharmacogenomics and pharmacogenetics in prostate cancer -- Functional and molecular imaging of prostate cancer -- Evaluation and assessment of molecular markers and their translation into clinical practice --
505 0 $aRegulatory aspects and implications of molecular testing in the United States.
520 $aWith the era of molecularly targeted therapy clearly established, prostate cancer is currently emerging as a forefront of discovery and implementation of personalized medicine strategies designed to individually select the best available treatment for each patient. This is the first book of its kind to focus on the molecular aspects of prostate cancer and how genetics, genomics and proteomics interact in the predisposition, development, progression and response to therapy of the disease. It emphasizes the genes, proteins and biologic pathways that are being evaluated today and will be tested in the future to derive the molecular signature of each newly diagnosed prostate cancer. This single volume offers readers relevant, up-to-date information on how these molecular-based tests are being used to discover the predisposition for developing the disease, how to detect it at the earliest stage possible, how to classify it based on its genetic fingerprint, and how to predict its therapy-specific outcome.
650 12 $aProstatic Neoplasms.
650 0 $aProstate$xCancer$xMolecular aspects.
700 1 $aRoss, Jeffrey S.$q(Jeffrey Stuart),$d1945-
700 1 $aFoster, Christopher.
988 $a20070604
906 $0OCLC